Current Capabilities
AD v PS RUO Assay Biomarker AnalysisAD v PS RUO Assay
Epidermal skin samples were non-invasively collected from the lesional skin of the patients (participants in IRB approved protocol) with moderate to severe AD or moderate to severe PS. RNA was then isolated and analyzed by quantitative real-time PCR for expression of the following biomarkers:
- AD associated biomarkers: IL-4R, IL-13, CCL17/TARC, CCL26/Eotaxin 3
- PS associated biomarkers: IL-17A, IL-22, IL-23A, NOS2, CXCL9, CXCL10
Using a machine learning approach, we identified a unique ratio that stratified AD versus PS subjects. The algorithm uses a combination of expression from IL-17A and NOS2 compared to the combined expression of CCL17 and IL-13.4
Contact us to learn more about this research use only assay for your clinical trials.
Using a machine learning approach, we identified a unique ratio that stratified AD versus PS subjects. The algorithm uses a combination of expression from IL-17A and NOS2 compared to the combined expression of CCL17 and IL-13.4
Contact us to learn more about this research use only assay for your clinical trials.

Send us a message
Click the contact us button and drop us a line. We'll be in touch shortly.
Get In Touch
Partner with DermTech today.
- Silverberg. Dermatol Clin. 2017
- Armstrong et al. JAMA Dermatol. 2021
- Hawerkamp et al. Skin Health Dis. 2022;e99.
- https://dermtechstratum.com/wp-content/uploads/SID-Poster_AD-vs-PS_FINAL.pdf